Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Pursuant to a borrowing notice CVRx, Inc. (the "Company") provided to Innovatus Life Sciences Fund I, LP ("Innovatus"), the Company borrowed $15.0 million under the second tranche of its term loan facility with Innovatus on Friday, December 15, 2023, the deadline for drawing the second tranche. Following this draw, the Company has $30.0 million in outstanding term loans under the Innovatus facility. The term loan facility provides an additional tranche of up to $20.0 million, based on the timing and other conditions set forth in the loan agreement.
CVRx Inc. published this content on 15 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 December 2023 21:35:19 UTC.
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
CVRX, INC. 
